国产bbaaaaa片,成年美女黄网站色视频免费,成年黄大片,а天堂中文最新一区二区三区,成人精品视频一区二区三区尤物

首頁> 美國衛(wèi)生研究院文獻(xiàn)>American Journal of Stem Cells >Viability assessment of human peripheral blood-derived stem cells after three methods of nebulization
【2h】

Viability assessment of human peripheral blood-derived stem cells after three methods of nebulization

機(jī)譯：三種霧化方法后人外周血來源干細(xì)胞的活力評估

代理獲取
本網(wǎng)站僅為用戶提供外文OA文獻(xiàn)查詢和代理獲取服務(wù)，本網(wǎng)站沒有原文。下單后我們將采用程序或人工為您竭誠獲取高質(zhì)量的原文，但由于OA文獻(xiàn)來源多樣且變更頻繁，仍可能出現(xiàn)獲取不到、文獻(xiàn)不完整或與標(biāo)題不符等情況，如果獲取不到我們將提供退款服務(wù)。請知悉。
  • 摘要
  • 著錄項
  • 相關(guān)主題

摘要

Background and objectives: Drug delivery by nebulization has become a crucial strategy for treating different respiratory and lung diseases. Emerging evidence implicates stem cell therapy as a promising tool in treating such conditions, not only by alleviating the related symptoms but by improving the prognosis. However, delivery of human peripheral blood-derived stem cells (hPBSCs) to the respiratory airways remains an innovative approach yet to be realized. This study is an analytic, translational, and in vitro research to assess the viability and morphological changes of identified cell populations in hPBSCs cocktail derived from COVID-19 patients. Methods and results: Peripheral blood (PB) samples were obtained from patients enrolled in the SENTAD-COVID Study (ClinicalTrials.gov Reference: NCT04473170). hPBSCs cocktails (n=15) were provided by the Cells Processing Laboratory of Abu Dhabi Stem Cells Center, and were nebulized by three different methods of nebulization: compressor (jet), ultrasonic, and mesh. Our results reported that nucleated CD45dim cell count was significantly lower after the three nebulization methods, but nucleated CD45- cells show a significant decrease only after mesh nebulization. Mesh-nebulized samples had a significant reduction in viability of both CD45dim and CD45- cells. Conclusions: This study provides evidence that stem cells derived from PB of COVID-19 patients can be nebulized without substantial loss of cell viability, cell count, and morphological changes using the compressor nebulization. Therefore, we recommend compressor nebulizers as the preferable procedure for hPBSCs delivery to the respiratory airways in further clinical settings.
機(jī)譯：背景和目標(biāo)： 霧化給藥已成為治療不同呼吸系統(tǒng)和肺部疾病的重要策略。新出現(xiàn)的證據(jù)表明，干細(xì)胞療法是治療此類疾病的一種有前途的工具，不僅可以緩解相關(guān)癥狀，還可以改善預(yù)后。然而，將人外周血來源的干細(xì)胞 （hPBSC） 遞送到呼吸道仍然是一種尚未實現(xiàn)的創(chuàng)新方法。本研究是一項分析、轉(zhuǎn)化和體外研究，旨在評估源自 COVID-19 患者的 hPBSCs 雞尾酒中已鑒定細(xì)胞群的活力和形態(tài)變化。方法和結(jié)果： 外周血 （PB） 樣本來自參加 SENTAD-COVID 研究的患者 （ClinicalTrials.gov 參考文獻(xiàn)：NCT04473170）。hPBSCs 混合物 （n=15） 由阿布扎比干細(xì)胞中心細(xì)胞加工實驗室提供，并通過三種不同的霧化方法進(jìn)行霧化：壓縮機(jī)（噴射）、超聲波和網(wǎng)片。我們的結(jié)果報告稱，三種霧化方法后有核 CD45dim 細(xì)胞計數(shù)顯著降低，但有核 CD45- 細(xì)胞僅在網(wǎng)狀霧化后顯示顯著降低。網(wǎng)狀霧化樣品的 CD45dim 和 CD45- 細(xì)胞活力均顯著降低。結(jié)論：本研究提供的證據(jù)表明，使用壓縮式霧化可以霧化來自 COVID-19 患者 PB 的干細(xì)胞，而不會顯著損失細(xì)胞活力、細(xì)胞計數(shù)和形態(tài)變化。因此，我們建議在進(jìn)一步的臨床環(huán)境中將壓縮機(jī)霧化器作為將 hPBSCs 輸送到呼吸氣道的首選程序。

著錄項

代理獲取

客服郵箱：kefu@zhangqiaokeyan.com

京公網(wǎng)安備：11010802029741號 ICP備案號：京ICP備15016152號-6 六維聯(lián)合信息科技 (北京) 有限公司?版權(quán)所有

  • 客服微信

  • 服務(wù)號